Fallopian tube cancer

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…

Researchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…

Researchers are testing whether adding inhaled manganese chloride to standard chemotherapy and an anti-PD-1 immunotherapy can help people with advanced ovarian cancer that has worsened after at least two prior treatments. The trial enrolls about 120 participants and randomly assi…

This phase 3 trial tests whether adding a gene therapy called IMNN-001 (given into the abdomen) to standard chemotherapy helps people with advanced ovarian, fallopian tube, or peritoneal cancer live longer. About 500 newly diagnosed patients will be randomly assigned to receive e…

This study tests whether adding the experimental drug IMNN-001 to standard chemotherapy and bevacizumab can better eliminate remaining cancer in people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. About 30 participants will be randomly assi…

This phase 2 trial is testing an experimental drug called ubamatamab, alone or combined with other cancer drugs, in 220 people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The study aims to see how…

This study tests a new drug called raludotatug deruxtecan (R-DXd) in people whose high-grade serous ovarian, peritoneal, or fallopian tube cancer has returned after platinum chemotherapy. R-DXd is an antibody-drug conjugate that seeks out cancer cells and delivers a toxic payload…

This study is testing a new drug called ubamatamab, given alone or with another drug called cemiplimab, in people with ovarian cancer or other cancers that have come back after treatment. The main goals are to check safety, find the right dose, and see if the drugs can shrink tum…

This Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…

This Phase 3 trial tests whether adding the experimental drug Rina-S to standard care (bevacizumab or monitoring) can help keep platinum-sensitive ovarian cancer from returning after chemotherapy. About 528 participants will receive either Rina-S alone, Rina-S plus bevacizumab, b…

This study tests whether giving the targeted drug mirvetuximab soravtansine together with standard chemotherapy (carboplatin) before surgery can shrink advanced ovarian, fallopian tube, or peritoneal cancers that have a specific protein (FRα). About 140 adults with stage III or I…

This phase 3 trial compares a new drug called Rina-S to standard chemotherapy in 82 people with platinum-resistant ovarian cancer. Participants are randomly assigned to receive either Rina-S or one of four approved chemotherapies. The goal is to see if Rina-S can delay cancer gro…

This study tests a new drug called AZD4956, alone or with other cancer drugs, in people with advanced or spreading solid tumors that have a specific DNA repair defect (HRR deficiency). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. …

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This phase 3 trial tests whether a new drug, sacituzumab tirumotecan, given with or without bevacizumab, can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer worsening. About 770 participants who have already completed two rounds of ch…

This trial is testing whether an experimental drug called TUB-040, when added to standard chemotherapy and a targeted therapy, is safe and tolerable for women with a specific type of advanced ovarian cancer. The study involves about 72 participants whose cancer has returned but s…

This large Phase 3 trial will test a new drug called Rina-S, alone or with bevacizumab, against standard platinum-based chemotherapy for women with ovarian cancer that has returned after initial treatment. About 688 participants will be randomly assigned to receive either the new…

This Phase 3 study tests whether a modified virus called Olvi-Vec, given with chemotherapy and bevacizumab, can help women with ovarian cancer that no longer responds to platinum drugs. About 186 participants will receive either the virus combination or standard chemotherapy. The…

This early-stage trial is testing a new drug called XmAb541 in people with advanced ovarian, endometrial, or germ cell tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and to find the best dose. About 282 participants will receive…

This study looks at how well niraparib works as a first-line maintenance therapy for women with advanced ovarian cancer when used in everyday clinical practice. It will follow about 1,920 patients who have completed initial chemotherapy and are now taking niraparib to keep the ca…

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

This early-phase trial tests a new drug called BGB-B455 in about 90 people with advanced or metastatic solid tumors that have a specific protein (CLDN6). The main goals are to find a safe dose and see what side effects occur. The study has two parts: first finding the right dose,…

This Phase 2 trial tests mirvetuximab soravtansine, a targeted drug, combined with standard chemotherapy (carboplatin) or bevacizumab in 400 people with a specific type of ovarian cancer (FRα-positive). The study aims to find the best dose and combination to shrink tumors and con…

This study tests an experimental drug called REGN5668, alone or combined with other drugs, in people with ovarian, fallopian tube, peritoneal, or endometrial cancer. The trial has two parts: first to find the safest dose, then to see if the drug shrinks tumors. About 612 particip…

This early-stage trial is testing an experimental drug called SIM0505 in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug shrinks tumors. About 414 participants will re…

This phase 2 trial tests whether adding an experimental immune-boosting drug (CDX-1140) to two standard immunotherapies (pembrolizumab and bevacizumab) can shrink tumors in people whose ovarian cancer has returned. About 80 adults with recurrent ovarian, fallopian tube, or perito…

This study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 p…

This study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …

This study looks at how well women of African ancestry with ovarian cancer tolerate a maintenance drug called niraparib after initial treatment. Researchers want to see if genetic or environmental factors affect side effects and how the drug works. About 70 women will take nirapa…

This study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…

This study tests an experimental drug called ART0380, taken as a pill, in people with advanced or metastatic solid tumors (cancers that have spread). The drug targets a protein that helps cancer cells repair their DNA. Researchers want to find the safest dose when given alone or …

This study tests whether giving heated chemotherapy directly into the abdomen during surgery is safe for women aged 70 and older with advanced ovarian cancer. The treatment, called NIPEC with carboplatin, is delivered at normal body temperature for 90 minutes right after the surg…

This study tests a new drug called raludotatug deruxtecan (R-DXd) in people with ovarian, peritoneal, or fallopian tube cancer that no longer responds to platinum chemotherapy. The drug is designed to target and kill cancer cells while sparing healthy ones. About 860 participants…

This study tests whether women with advanced ovarian cancer who have had all visible tumor removed can safely receive only 3 cycles of chemotherapy instead of the standard 6, followed by a maintenance drug called niraparib. The goal is to see if the shorter chemo is just as effec…

This early-phase study tests whether combining two drugs, Cirtuvivint and Olaparib, is safe for women with ovarian cancer that no longer responds to platinum chemotherapy. About 50 participants will take the medications on different schedules and visit the clinic regularly for ch…

This Phase 3 trial is testing a new drug called AZD5335 against standard treatments (like chemotherapy or another targeted drug) in about 1,100 women with a tough-to-treat type of ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if AZD…

This early-phase trial tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or nab-paclitaxel and atezolizumab in 43 people with advanced solid tumors in the abdomen or chest. The goal is to find the safest dose and see if…

This study tests a drug called relacorilant, taken as a pill, combined with two standard chemotherapy drugs (nab-paclitaxel and bevacizumab) in people with ovarian, fallopian tube, peritoneal, or endometrial cancers. The goal is to see if the combination can slow cancer growth or…

This early-stage trial tests an investigational drug called ABBV-901, alone or with a standard drug bevacizumab, in about 219 adults with advanced ovarian cancer that no longer responds to platinum chemotherapy. The main goals are to check safety and see if the drug can shrink tu…

This study tests a new drug called mocertatug rezetecan (Mo-Rez) in 450 people with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if Mo-Rez helps people live longer without their cancer growing compared to standard treatments. Researchers…

This phase 2 trial is testing a combination of the targeted drug mirvetuximab soravtansine and the chemotherapy carboplatin as a first treatment for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific marker (folate receptor alpha). About…

This study tests whether adding tivozanib (a drug that targets blood vessel growth) to atezolizumab (an immunotherapy) can help the immune system attack cancers that normally resist immunotherapy. The trial includes people with several cancer types like bile duct, pancreatic, pro…

This study is testing whether a combination of two drugs, mirvetuximab soravtansine and olaparib, can help keep ovarian, peritoneal, or fallopian tube cancer from coming back after initial treatment. About 53 women with cancer that responded to platinum-based chemotherapy will re…

This study tests whether adding an experimental drug called TORL-1-23 to standard chemotherapy before surgery can help women with advanced ovarian cancer. About 60 participants with a specific tumor marker (CLDN6) will receive the combination, then undergo surgery. The goal is to…

This Phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy in 384 women with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatment. The goal is to see if BL-B01D1 can slow disease progression and impro…

This early-phase trial is testing how the antifungal drug itraconazole affects the levels of a new cancer drug, AZD5335, in the body. The study involves 24 people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum chemotherapy. The goal is …

This study tests a new drug called mocertatug rezetecan (Mo-Rez) combined with other cancer medicines for people with advanced solid tumors that have stopped responding to standard treatments. About 305 adults will join to see if the combination is safe, tolerable, and effective.…

This early-stage trial tests a new drug called MEN2501 in about 100 adults with ovarian cancer that has stopped responding to platinum chemotherapy. The main goals are to check safety and find the best dose. Researchers will also watch for signs that the drug shrinks tumors or sl…

This early-phase study tests a new drug called XMT-1660 in about 319 people with advanced solid tumors, including breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug shrinks tumors.…

This phase 2 trial is testing a combination of three drugs (carboplatin, paclitaxel, and pembrolizumab) given before surgery to shrink tumors in women with newly diagnosed stage III or IV ovarian cancer. After surgery, participants receive two maintenance drugs (olaparib and pemb…

This early-stage study is testing a new treatment called SynKIR-110 for people with advanced ovarian cancer, bile duct cancer, or mesothelioma that has spread or come back. The treatment involves taking a patient's own immune cells, engineering them in a lab to better recognize a…

This early-stage trial tests an experimental drug called mocertatug rezetecan in 675 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The main goals are to check safety, find the ri…

This phase 2 trial tests whether combining two oral drugs—ZEN003694 (a BET inhibitor) and talazoparib (a PARP inhibitor)—can shrink tumors in people with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Participants must have already received a PARP inhibitor befo…

This Phase 2 trial tests whether adding the experimental drug ONC201 to standard chemotherapy (paclitaxel) can help women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 62 participants will receive the combinatio…

This study tests a new drug called IMP1734 in people with advanced solid tumors (breast, ovarian, or prostate cancer) that have not responded to prior treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 156 participants will ta…

This early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesoth…

This early-phase trial is testing an experimental drug called CX-5461 (Pidnarulex) in people with advanced solid tumors (pancreatic, prostate, breast, or ovarian) that have specific BRCA2 or PALB2 gene mutations. The main goal is to find a safe and tolerable dose for future studi…

This study tests a new drug called MORAb-202 that targets a protein (folate receptor alpha) found on some cancer cells. It is for people with ovarian, endometrial, non-small cell lung, or triple-negative breast cancer. The trial has two parts: first to find the safest dose, then …

This study tests an experimental drug called IMGN151, alone or with other cancer treatments, in about 377 adults with gynecologic cancers like ovarian cancer. The goal is to check safety and find the best dose. Participants get the drug through an IV and will have regular check-u…

This study compares a new barbed suture (SYMMCORA) with a standard one (V-Loc) for closing the vaginal cuff after laparoscopic hysterectomy. The goal is to see if the new suture reduces stitching time without increasing complications. About 132 women having elective laparoscopic …

This early-stage study tests a new experimental drug (NMS-03305293) combined with a standard chemotherapy (topotecan) in about 24 people whose ovarian cancer has returned after previous treatments. The main goals are to check safety and find the best dose, while also seeing if th…

This early-stage trial tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The study will check for safety, side effects, and whether the drug can s…

This study tests a drug called mirvetuximab soravtansine (MIRV) in people with ovarian, peritoneal, or fallopian tube cancer that no longer responds to platinum chemotherapy and has high levels of a protein called FRα. The drug delivers a cancer-killing agent directly to tumor ce…

This study is for women with advanced ovarian, fallopian tube, or peritoneal cancer whose tumors did not shrink enough with standard chemotherapy. Researchers are testing a new method called PIPAC, which delivers chemotherapy as a pressurized spray directly into the abdomen, comb…

This study is for adults with certain cancers (like breast, lung, or ovarian) that are in complete remission but have persistently low platelet counts from past chemotherapy. It tests whether adding a vitamin A derivative (ATRA) to a standard platelet-boosting drug works better t…

This study tests a new treatment for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells (T-cells) that are genetically modified in a lab to recognize and attack a protein called PRAME found on cancer cel…

This pilot study tests whether adding the blood thinner tinzaparin to standard chemotherapy can improve outcomes for women with advanced ovarian cancer. About 40 participants will receive either chemotherapy plus tinzaparin or chemotherapy alone. The main goal is to see if tinzap…

This study looks at whether removing enlarged lymph nodes in the chest area during surgery can help people with advanced ovarian cancer live longer without the cancer coming back. About 52 women with stage III or IV ovarian cancer will take part. The goal is to see if this extra …

This study tests whether adding the experimental drug B013 to standard chemotherapy (paclitaxel) can help people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 90 participants will receive either the comb…

This study tests a new drug called IN10018 combined with standard chemotherapy in people with a tough-to-treat type of ovarian cancer that no longer responds to platinum-based drugs. About 150 adults will take part to see if the combination is safe and shrinks tumors. The goal is…

This study tests a drug called HLX43 in 190 people with advanced cervical or ovarian cancer that came back or spread after initial treatment. HLX43 is designed to deliver a toxin directly to cancer cells by targeting a protein called PD-L1. The goal is to see if it can shrink tum…

This phase 3 trial tests a new drug called SHR-A1811 against standard chemotherapy in 300 people with ovarian, fallopian tube, or primary peritoneal cancer that no longer responds to platinum-based treatment. The goal is to see if the new drug can slow cancer growth and improve s…

This Phase 2 trial tests whether trastuzumab deruxtecan (T-DXd), a targeted antibody-drug conjugate, works better than standard chemotherapy for recurrent ovarian cancer that has stopped responding to PARP inhibitors. About 116 participants whose tumors express the HER2 protein w…

This phase 3 trial tests whether giving heated chemotherapy directly into the abdomen during surgery helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer. About 220 participants will be randomly assigned to receive either heated chemo plus standard tre…

This study is for women with advanced ovarian cancer who have had complete surgery and chemotherapy. It compares two maintenance treatments: niraparib alone versus niraparib plus bevacizumab. The goal is to see which approach better delays cancer progression. About 390 participan…

This early-phase study tests a new drug called azenosertib (ZN-c3) combined with standard chemotherapy or bevacizumab in people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based treatment. About 172 participants will receive differen…

This study tests a technique called acute normovolemic hemodilution (ANH) in 86 women having surgery for advanced ovarian cancer. Before surgery, some blood is removed and stored, then returned during or after the operation. The goal is to see if this reduces the need for donor b…

This clinical trial tests whether the experimental antibody COM701 can delay the return of ovarian cancer in people whose cancer has come back but still responds to platinum chemotherapy. About 60 participants will receive COM701 or a placebo every three weeks as maintenance ther…

This study tests a new drug called CapsuleX combined with cisplatin in 40 people whose ovarian cancer no longer responds to platinum-based chemotherapy. The goal is to see if the combination can shrink tumors and how safe it is. Participants must have confirmed ovarian, fallopian…

This early-phase study tests a new personalized cell therapy called Innocell for people with recurrent epithelial ovarian cancer. The treatment uses a patient's own tumor tissue to create a custom immunotherapy. The main goals are to see if it is safe to give and if the body's im…

This study tests adding Ashwagandha (an herbal supplement) to standard chemotherapy (DOXIL) for people whose ovarian cancer has returned. The goal is to find a safe dose and see if the combination helps shrink tumors or slow cancer growth. About 72 participants with recurrent ova…

This study tests whether a PARP inhibitor combined with bevacizumab (Avastin) can delay cancer recurrence in people with advanced ovarian, fallopian-tube, or primary peritoneal cancer that has a specific DNA repair defect (HRD). About 120 participants will receive chemotherapy pl…

This early-phase trial is testing the drug talazoparib together with radiation therapy in 24 women whose gynecologic cancer (ovarian, endometrial, cervical, or related cancers) has come back after previous treatment. Talazoparib blocks enzymes that cancer cells need to grow, and …

This study tests a new approach for advanced ovarian cancer. Patients take a targeted drug (olaparib) for a week before surgery, then receive heated chemotherapy directly in the abdomen during the operation. The goal is to see if this combination is safe and effective. The trial …

This phase 2 trial is testing two oral drugs, fuzuloparib and apatinib, given before surgery to women with a specific genetic type (HRD-positive) of advanced ovarian cancer. The goal is to shrink tumors enough for complete surgical removal, potentially improving outcomes and avoi…

This Phase 3 trial tests whether adding heated chemotherapy (HIPEC) directly into the abdomen during surgery can help people with advanced ovarian cancer live longer. About 520 participants who have already had some chemo will be randomly assigned to get surgery with or without H…

This study tests a new drug called SPR1020 in adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to target cancer cells with specific genetic changes (BRCA or HRR mutations) and may also reach brain tumors. The goal is to find a…

This early-phase trial tests an experimental treatment called 27T51, a type of immune cell therapy (CAR T) designed to attack cancer cells that carry a protein called MUC16. The study includes about 90 women with ovarian, peritoneal, or fallopian tube cancer that has come back or…

This study tests a new drug called TORL-1-23 in women with advanced ovarian cancer that no longer responds to platinum-based chemotherapy. The drug targets a protein called claudin 6 found on cancer cells. About 230 women will receive the drug to see if it shrinks tumors and how …

This phase II trial tests whether combining two drugs that affect cell cleanup (hydroxychloroquine and nelfinavir) with standard maintenance therapy (bevacizumab) can help keep ovarian cancer from growing back. About 38 women with recurrent high-grade serous ovarian cancer will t…

This study tests a new drug called HS-20089 against standard chemotherapy for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 468 participants will be randomly assigned to receive either HS-20089 or…

This study tests a new drug called distamab vedotin (RC48) combined with carboplatin for people with advanced ovarian cancer that has a specific protein called HER2. The goal is to see if this combination works better and causes fewer side effects than standard chemotherapy. Abou…

This study is the first to test AVZO-021, an oral drug that blocks a protein called CDK2, in people with advanced solid tumors. The trial will enroll about 430 adults with certain breast, ovarian, or other cancers. The goal is to find safe doses and see if the drug can shrink tum…

This study is testing a surgery called hepato-celiac lymphadenectomy for people with advanced or recurrent ovarian cancer. The surgery removes lymph nodes near the liver and stomach that may contain cancer. The goal is to see if this extra step, along with standard tumor removal,…

This study tests if two drugs, senaparib and temozolomide, can shrink tumors in people with a certain type of ovarian cancer that has an ARID1A gene change. About 18 adults with recurrent or persistent clear cell or endometrioid ovarian, fallopian tube, or primary peritoneal canc…

This study tests whether having surgery to remove remaining tumors after chemotherapy helps people with recurrent ovarian cancer live longer. About 80 participants will be randomly assigned to either have surgery or not. The goal is to see if surgery can delay the cancer from com…

This Phase 3 trial is testing whether adding bevacizumab to niraparib after standard chemotherapy helps women with newly diagnosed advanced ovarian cancer stay cancer-free longer. About 970 participants will receive either niraparib alone or niraparib plus bevacizumab as maintena…

This study tests a drug called Gleolan that makes ovarian cancer cells glow during surgery. The goal is to help surgeons find and remove tumors they might otherwise miss. About 170 women with suspected or recurrent ovarian cancer will take part. The study lasts about two weeks pe…

This study tests a new device called DOvEEgene Fleur for collecting cells from inside the uterus to detect cancers of the endometrium, tubes, and ovaries. The goal is to see if it is less painful and easier to use than the current brush, while still collecting enough cells for ac…

This study is testing a new way to detect ovarian cancer early. Researchers will take a sample of fluid from the womb (uterine lavage) and a blood sample from 250 women before they have surgery for a suspected ovarian growth. After surgery, they will check whether the woman had c…

This study looks at whether removing the fallopian tubes first and delaying ovary removal is as safe as removing both at once to prevent ovarian cancer in women with BRCA or other high-risk gene mutations. About 100 premenopausal women will choose either the new two-step approach…

This phase 2 trial tests whether guarana, a natural supplement from the Amazon, can reduce fatigue in 86 people with neuroendocrine tumors or gynecologic cancers. Participants take either guarana or a placebo daily for up to 42 days, and researchers measure changes in fatigue usi…

This study tests a comprehensive yoga therapy program for women with advanced ovarian cancer who are scheduled for chemotherapy and surgery. The program includes dietary advice, movement, breathing exercises, and mental support. Researchers want to see if it is feasible and if it…

This study tests whether N-Acetyl-Cysteine (NAC), a supplement, can reduce chemotherapy-related cognitive impairment (often called 'chemo brain') in ovarian cancer patients. About 102 postmenopausal women with advanced ovarian cancer receiving platinum-based chemotherapy will tak…

This pilot study tests whether a combination of stress-reducing drugs (propranolol and etodolac) and mind-body techniques (resilience training and music therapy) can help women with advanced ovarian cancer feel less stress before, during, and after surgery. The study will enroll …

This study tests a telehealth program called REVITALIZE to see if it can reduce how much fatigue interferes with daily life for adults with advanced ovarian cancer who are taking PARP inhibitors. About 240 participants will either receive the REVITALIZE program or educational mat…

This study looks at whether alternate day fasting (eating very little every other day) before chemotherapy can help reduce side effects and improve quality of life for women with ovarian, endometrial, or uterine cancer. About 30 women who have had surgery and are about to start c…

This study tests whether a personalized physical activity program using a wearable device (like a Fitbit) can help people with ovarian or endometrial cancer exercise more and improve their quality of life. About 120 participants will either receive tailored activity goals and fee…

Researchers at the University of New Mexico collect ascites fluid, the liquid that builds up in the abdomen, from women undergoing surgery for ovarian cancer. They study this fluid and tumor tissue in the lab to learn how the tumor environment helps cancer spread within the perit…

This study looks at tissue samples from 200 people with relapsed ovarian, fallopian tube, or primary peritoneal cancer to see how often a protein called folate receptor alpha (FRα) is present at high levels. The goal is to understand how common this protein is, which may help doc…

This observational registry is gathering data from 500 adults whose gynecologic cancer has returned after prior radiation therapy. Doctors are using reirradiation or other ablative strategies as part of standard care, and the registry will track how well these treatments control …

This study collects tumor and blood samples from 3,300 people at high genetic risk for breast, ovarian, and related cancers. Researchers want to learn how these cancers develop and how well treatments work. Participants include those with BRCA1/2 or other gene mutations, or a str…

This early-stage study tests a small implantable device that is placed directly into tumors to see how different drugs work against ovarian, fallopian tube, and peritoneal cancers. About 20 people with advanced cancer will receive the device during standard surgery. The goal is t…

This study aims to create a shared decision-making tool for Spanish-speaking women with advanced ovarian cancer. The tool will help them and their doctors discuss and choose maintenance therapy after chemotherapy. About 70 patients will test the tool to see if it reduces regret a…

This study looks at 371 people with advanced ovarian, peritoneal, or fallopian tube cancer to find out what factors—like age, tumor type, and genetics—are linked to how long they live. Researchers will collect medical data and blood samples over two years. The goal is to build a …

This study is testing whether a polygenic risk score (PRS) — a calculation based on many small genetic variations — can help predict a woman's chance of developing ovarian cancer. Researchers will compare the PRS of 1,300 Italian women, half with ovarian cancer and half without. …

This study follows 1,000 women newly diagnosed with epithelial ovarian cancer to see how their genetic makeup (BRCA and HRD status) influences their response to standard treatments. Researchers will track surgery outcomes, treatment response, and survival. The goal is to gather r…

This study is testing a new blood test that looks for tumor DNA (ctDNA) to see if it can find ovarian cancer coming back earlier than current methods like CT scans or CA-125 blood tests. About 30 women with advanced ovarian cancer will give blood samples over time during their fo…

This study is looking at immune markers in the blood of 300 women with ovarian cancer to see if they can predict how the disease will progress. It is an observational study, meaning no treatment is given. The goal is to better understand the role of the immune system in ovarian c…

This study aims to learn how gene and protein changes in gynecologic tumors affect cancer behavior and treatment response. Researchers will collect tumor tissue and blood samples from 1,000 people with ovarian, uterine, cervical, or other gynecologic cancers. The goal is to bette…

This study looks at whether a blood test can find genetic changes in tumor DNA that signal ovarian cancer is coming back. It involves 130 women with BRCA mutations who are taking a maintenance drug called Olaparib after initial treatment. The goal is to see if these blood tests c…